Summary:

In this presentation, Dr. David Liu (Dana-Farber Cancer Institute) explores how clinical and molecular data from melanoma patients can reveal key drivers of immunotherapy resistance and tumor evolution. Through advanced computational modeling and in-depth patient profiling, Dr. Liu highlights predictive biomarkers—including genomic heterogeneity, tumor ploidy, and hypoxia signatures—and shows how these features inform treatment decisions and therapeutic response. This webinar offers valuable insights for researchers working to understand and overcome resistance to immune checkpoint blockade. 

Topics to be covered:

  • Biomarkers of resistance to anti-PD-1 therapy in melanoma
  • Impact of hypoxia and the tumor microenvironment on immunotherapy outcomes
  • Tumor evolution and clonal dynamics revealed through longitudinal patient profiling

Speakers:

Learning from Resistance: Clinical Insights to Guide Functional Antibody Research Featuring Dr. David Liu, Dana-Farber Cancer Institute David Liu, MD, MPH
Assistant Professor, Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Associate Member, Broad Institute of Harvard and MIT